Albuminuria and risk of cardiovascular events, death, and heart failure indiabetic and nondiabetic individuals

Context Microalbuminuria is a risk factor for cardiovascular (CV) events. T he relationship between the degree of albuminuria and CV risk is unclear. Objectives To estimate the risk of CV events in high-risk individuals with diabetes mellitus (DM) and without DM who have microalbuminuria and to dete rmine whether levels of albuminuria below the microalbuminuria threshold in crease CV risk. Design The Heart Outcomes Prevention Evaluation study, a cohort study condu cted between 1994 and 1999 with a median 4.5 years of follow-up. Setting Community and academic practices in North and South America and Eur ope. Participants Individuals aged 55 years or more with a history of CV disease (n=5545) or DM and at least 1 CV risk factor (n =3498) and a baseline urin e albumin/creatinine ratio (ACR) measurement. Main Outcome Measures Cardiovascular events (myocardial infarction, stroke, or CV death); all-cause death; and hospitalization for congestive heart fa ilure. Results Microalbuminuria was detected in 1140 (32.6%) of those with DM and 823 (14.8%) of those without DM at baseline. Microalbuminuria increased the adjusted relative risk (RR) of major CV events (RR, 1.83; 95% confidence i nterval [CI], 1.64-2.05), all-cause death (RR, 2.09; 95% CI, 1.84-2.38), an d hospitalization for congestive heart failure (RR, 3.23; 95% CI, 2.54-4.10 ). Similar RRs were seen for participants with or without DM, even after ad justing for other CV risk factors (eg, the adjusted RR of the primary aggre gate end point was 1.97 [95% CI, 1.68-2.31] in those with DM and 1.61 [95% CI, 1.36-1.90] in those without DM). Compared with the lowest quartile of A CR (<0.22 mg/mmol), the RRs of the primary aggregate end point in the secon d quartile (ie, ACR range, 0.22-0.57 mg/mmol) was 1.11 (95 % CI, 0.95-1.30) ; third quartile, 1.38 (95 % CI, 1.19-1.60; ACR range, 0.58-1.62 mg/mmol); and fourth quartile, 1.97 (95% CI, 1.73-2.25; ACR range, >1.62 mg/mmol) (P for trend <.001, even after excluding those with microalbuminuria). For eve ry 0.4-mg/mmol increase in ACR level, the adjusted hazard of major CV event s increased by 5.9% (95% CI, 4.9%-7.0%). Conclusions Our results indicate that any degree of albuminuria is a risk f actor for CV events in individuals with or without DM; the risk increases w ith the ACR, starting well below the microalbuminuria cutoff. Screening for albuminuria identifies people at high risk for CV events.